Orasis Pharmaceuticals
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company with offices in the United States and Israel, focused on treatments for presbyopia — the age-related loss of near vision that affects roughly two billion people worldwide. Its lead product, QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%, is a preservative-free, single-use-vial prescription eye drop approved by the FDA in October 2023 and commercially available in the United States, with a follow-on candidate (BESKA) submitted for approval in Australia. The company is backed by life-sciences investors including Sequoia Capital, Johnson & Johnson Innovation and Arboretum Ventures. Orasis sells a regulated pharmaceutical product, not software: it operates a corporate marketing site plus product sites for patients (qlosi.com) and eye care professionals (qlosiecp.com), and publishes no developer program, public API, SDK, webhook surface or machine-readable API contract of any kind.
Orasis Pharmaceuticals is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Life Sciences, Ophthalmology, and Healthcare.
Orasis Pharmaceuticals’ developer surface includes support, engineering blog, and 6 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 3
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.